As of the end of 2025, 213 children and young adults have been identified worldwide as living with progeria or closely related conditions. Of those, 155 have Hutchinson-Gilford Progeria Syndrome (HGPS), the classic form of progeria, while the remaining 58 have related progeroid laminopathies. These individuals live across 51 countries.
Why the Number Is So Low
Progeria occurs in roughly 1 in every 4 million live births. With about 140 million babies born globally each year, that translates to only around 35 new cases annually across the entire planet. The condition has no gender, ethnic, or geographic bias. It strikes randomly in every population at the same rate.
Nearly all cases are caused by a spontaneous genetic mutation, not one inherited from a parent. A child can be born with progeria in any family, in any country, with no prior warning. The odds of it happening to any given couple are vanishingly small, and parents who have one affected child face only a slightly elevated risk in future pregnancies.
The Gap Between Identified and Actual Cases
The 213 figure represents identified cases, not the total number of people living with the condition. The Progeria Research Foundation, which maintains the most comprehensive global registry, uses population-based estimates to project how many undiagnosed children are likely out there. Because the birth incidence is consistent worldwide, researchers can look at any country’s total population and estimate how many progeria cases should exist there, then compare that to how many have actually been found.
In the United States and other countries with robust medical systems, most children with progeria are eventually identified. But in parts of the world with limited access to genetic testing or specialist care, many cases go undiagnosed. A child in a remote area might show the characteristic signs, including growth failure, hair loss, and aged-looking skin, without ever receiving a formal diagnosis or connecting with the global research community. The true worldwide number of people living with progeria at any given time is estimated to be several hundred, meaning a significant fraction remain unidentified.
How Progeria Is Recognized
Babies with progeria typically appear healthy at birth. The first visible signs usually emerge during the first or second year of life, when a child fails to gain weight normally and develops distinctive skin changes. Over time, the signs become unmistakable: hair thins or falls out completely, veins become visible beneath tight skin, and the face takes on a characteristic narrow shape with a small jaw and prominent eyes.
Historically, doctors relied entirely on these physical features to make a diagnosis. Today, genetic testing can confirm the specific mutation responsible, which allows for earlier and more definitive identification. That shift has helped the Progeria Research Foundation locate and connect with more families around the world, though the diagnostic gap in lower-resource countries remains substantial.
Life Expectancy and Treatment
The average age of death for someone with classic progeria is 14.5 years. Children with the condition experience dramatically accelerated cardiovascular aging, and most die from heart attacks or strokes that would typically affect someone decades older.
The first treatment specifically approved for progeria, a drug called Zokinvy, changed the outlook meaningfully. In studies with up to 11 years of follow-up, children treated with Zokinvy lived an average of 2.5 years longer than untreated patients. That may sound modest, but in the context of a condition where most children don’t reach their mid-teens, an additional 2.5 years represents a significant extension, roughly 17% more life. The drug works by blocking the buildup of an abnormal protein that damages cells and drives the accelerated aging process.
Why Tracking Every Case Matters
With so few people affected worldwide, every identified case has outsized importance for research. Clinical trials for rare diseases struggle to enroll enough participants, so locating undiagnosed children isn’t just a humanitarian goal. It directly shapes how quickly new treatments can be tested and how well scientists understand the condition’s full range of outcomes. The Progeria Research Foundation actively searches for unidentified cases in countries where population estimates suggest children should exist but haven’t been found, working with local medical communities to close the gap.
The rarity also means that progeria research punches above its weight in broader science. The same protein malfunction that causes progeria plays a role in normal aging, making these few hundred children a window into cardiovascular disease and cellular aging that affects billions of people.